These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
160 related articles for article (PubMed ID: 22235243)
1. Influence of IL28B polymorphisms on response to a lower-than-standard dose peg-IFN-α 2a for genotype 3 chronic hepatitis C in HIV-coinfected patients. López-Cortés LF; Ruiz-Valderas R; Jimenez-Jimenez L; González-Escribano MF; Torres-Cornejo A; Mata R; Rivero A; Pineda JA; Marquez-Solero M; Viciana P; PLoS One; 2012; 7(1):e28115. PubMed ID: 22235243 [TBL] [Abstract][Full Text] [Related]
2. Impact of the peginterferon-α 2a and ribavirin plasma levels on viral kinetics and sustained virological response in genotype 1 HCV/HIV-co-infected patients with the unfavourable non-CC IL28B genotypes. Torres-Cornejo A; Ruiz-Valderas R; Jimenez-Jimenez L; Abad-Molina C; Gutierrez-Valencia A; Viciana P; Lopez-Cortes LF J Viral Hepat; 2014 Mar; 21(3):178-88. PubMed ID: 24438679 [TBL] [Abstract][Full Text] [Related]
3. IL28B gene polymorphisms and viral kinetics in HIV/hepatitis C virus-coinfected patients treated with pegylated interferon and ribavirin. Rallón NI; Soriano V; Naggie S; Restrepo C; Goldstein D; Vispo E; McHutchison J; Benito JM AIDS; 2011 May; 25(8):1025-33. PubMed ID: 21505315 [TBL] [Abstract][Full Text] [Related]
4. Randomized trial of peginterferon α-2a plus ribavirin versus peginterferon α-2b plus ribavirin for chronic hepatitis C in Japanese patients. Miyase S; Haraoka K; Ouchida Y; Morishita Y; Fujiyama S J Gastroenterol; 2012 Sep; 47(9):1014-21. PubMed ID: 22382633 [TBL] [Abstract][Full Text] [Related]
5. Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: a systematic review and economic evaluation. Hartwell D; Jones J; Baxter L; Shepherd J Health Technol Assess; 2011 Apr; 15(17):i-xii, 1-210. PubMed ID: 21473834 [TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of daclatasvir plus pegylated-interferon alfa 2a and ribavirin in previously untreated HCV subjects coinfected with HIV and HCV genotype-1: a Phase III, open-label study. Sulkowski MS; Fessel WJ; Lazzarin A; Berenguer J; Zakharova N; Cheinquer H; Côté P; Dieterich D; Gadano A; Matthews G; Molina JM; Moreno C; Pineda JA; Pulido F; Rivero A; Rockstroh J; Hernandez D; McPhee F; Eley T; Liu Z; Mendez P; Hughes E; Noviello S; Ackerman P Hepatol Int; 2017 Mar; 11(2):188-198. PubMed ID: 28210927 [TBL] [Abstract][Full Text] [Related]
7. Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trial. Sulkowski MS; Sherman KE; Dieterich DT; Bsharat M; Mahnke L; Rockstroh JK; Gharakhanian S; McCallister S; Henshaw J; Girard PM; Adiwijaya B; Garg V; Rubin RA; Adda N; Soriano V Ann Intern Med; 2013 Jul; 159(2):86-96. PubMed ID: 23685940 [TBL] [Abstract][Full Text] [Related]
8. Comparison of high ribavirin induction versus standard ribavirin dosing, plus peginterferon-α for the treatment of chronic hepatitis C in HIV-infected patients: the PERICO trial. Labarga P; Barreiro P; da Silva A; Guardiola JM; Rubio R; Aguirrebengoa K; Miralles P; Portu J; Téllez MJ; Morano L; Castro A; Pineda JA; Terrón A; Hernández-Quero J; Mariño A; Ríos MJ; Echeverría S; Asensi V; Vispo E; Soriano V; J Infect Dis; 2012 Sep; 206(6):961-8. PubMed ID: 22807523 [TBL] [Abstract][Full Text] [Related]
9. Temperature rise after peginterferon alfa-2a injection in patients with chronic hepatitis C is associated with virological response and is modulated by IL28B genotype. Han H; Noureddin M; Witthaus M; Park YJ; Hoofnagle JH; Liang TJ; Rotman Y J Hepatol; 2013 Nov; 59(5):957-63. PubMed ID: 23850879 [TBL] [Abstract][Full Text] [Related]
10. Open, randomized, multicentre italian trial on PEG-IFN plus ribavirin versus PEG-IFN monotherapy for chronic hepatitis C in HIV-coinfected patients on HAART. Cargnel A; Angeli E; Mainini A; Gubertini G; Giorgi R; Schiavini M; Duca P; Antivir Ther; 2005; 10(2):309-17. PubMed ID: 15865225 [TBL] [Abstract][Full Text] [Related]
11. Both Hepatitis C Virus-Specific T Cell Responses and IL28B rs12979860 Single-Nucleotide Polymorphism Genotype Influence Antihepatitis C Virus Treatment Outcome in Patients with Chronic Hepatitis C. Benito JM; García-Samaniego J; García M; Madejón A; Martín-Carbonero L; Cabello A; Álvarez B; Górgolas M; Rallón N J Interferon Cytokine Res; 2017 Jun; 37(6):278-286. PubMed ID: 28440692 [TBL] [Abstract][Full Text] [Related]
12. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. Chung RT; Andersen J; Volberding P; Robbins GK; Liu T; Sherman KE; Peters MG; Koziel MJ; Bhan AK; Alston B; Colquhoun D; Nevin T; Harb G; van der Horst C; N Engl J Med; 2004 Jul; 351(5):451-9. PubMed ID: 15282352 [TBL] [Abstract][Full Text] [Related]
13. Early virologic response and IL28B polymorphisms in patients with chronic hepatitis C genotype 3 treated with peginterferon alfa-2a and ribavirin. Scherzer TM; Hofer H; Staettermayer AF; Rutter K; Beinhardt S; Steindl-Munda P; Kerschner H; Kessler HH; Ferenci P J Hepatol; 2011 May; 54(5):866-71. PubMed ID: 21145807 [TBL] [Abstract][Full Text] [Related]
14. Value of interleukin-28B genetic polymorphism on retreatment outcomes of chronic hepatitis C genotype 1 relapsers by peginterferon alfa plus ribavirin. Chen MY; Liu CH; Chen TC; Su TH; Chen PJ; Chen DS; Kao JH; Liu CJ J Gastroenterol Hepatol; 2014 Jan; 29(1):102-9. PubMed ID: 23829453 [TBL] [Abstract][Full Text] [Related]
15. Pegylated interferon plus ribavirin is suboptimal in IL28B CC carriers without rapid response. Neukam K; Barreiro P; Rivero-Juárez A; Caruz A; Mira JA; Camacho A; Macías J; Rivero A; Soriano V; Pineda JA J Infect; 2013 Jul; 67(1):59-64. PubMed ID: 23542783 [TBL] [Abstract][Full Text] [Related]
16. Analysis of IL28B alleles with virologic response patterns and plasma cytokine levels in HIV/HCV-coinfected patients. Fernández-Rodríguez A; Rallón N; Berenguer J; Jiménez-Sousa MA; Cosín J; Guzmán-Fulgencio M; Restrepo C; Lopez JC; García-Álvarez M; Miralles P; Soriano V; Benito JM; Resino S AIDS; 2013 Jan; 27(2):163-73. PubMed ID: 23135173 [TBL] [Abstract][Full Text] [Related]
17. Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin. Yu JW; Wang GQ; Sun LJ; Li XG; Li SC J Gastroenterol Hepatol; 2007 Jun; 22(6):832-6. PubMed ID: 17565637 [TBL] [Abstract][Full Text] [Related]
18. Interferon-λ3 polymorphisms in pegylated-interferon-α plus ribavirin therapy for genotype-2 chronic hepatitis C. Ishiguro H; Abe H; Seki N; Sugita T; Aida Y; Itagaki M; Sutoh S; Shimada N; Furihata T; Tsubota A; Aizawa Y World J Gastroenterol; 2015 Apr; 21(13):3904-11. PubMed ID: 25852275 [TBL] [Abstract][Full Text] [Related]
19. Interferon-stimulated genes are associated with peginterferon/ribavirin treatment response regardless of IL28B alleles in hepatitis C virus/HIV-coinfected patients. Rallon NI; Lopez-Fernandez LA; Garcia MI; Benguria A; Fiorante S; Soriano V; Benito JM AIDS; 2013 Mar; 27(5):687-96. PubMed ID: 23196939 [TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of peg-IFN alfa-2a with ribavirin for the treatment of HCV/HIV coinfected patients who failed previous IFN based therapy. Rodríguez-Torres M; Rodríguez-Orengo JF; Ríos-Bedoya CF; Fernández-Carbia A; González-Lassalle E; Salgado-Mercado R; Marxuach-Cuétara AM J Clin Virol; 2007 Jan; 38(1):32-8. PubMed ID: 17064957 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]